Please login to the form below

Not currently logged in
Email:
Password:

enoxaparin

This page shows the latest enoxaparin news and features for those working in and with pharma, biotech and healthcare.

Portola rejection hands advantage to Boehringer's Pradaxa

Portola rejection hands advantage to Boehringer's Pradaxa

Johnson &Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.

Latest news

More from news
Approximately 0 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    To address some of these limitations, subcutaneously administered low molecular weight heparins (LMWHs), such as enoxaparin (Clexane/Lovenox; Sanofi), were developed. ... Results from this trial showed that LY 517717 appeared to be as effective as

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics